PIM
Platinum Investment Management Portfolio holdings
AUM
$1.5B
This Quarter Return
+28.48%
1 Year Return
+16.62%
3 Year Return
+100.57%
5 Year Return
+187.54%
10 Year Return
+422.09%
AUM
$4.35B
AUM Growth
+$4.35B
(+7.6%)
Cap. Flow
-$515M
Cap. Flow
% of AUM
-11.84%
Top 10 Holdings %
Top 10 Hldgs %
52.87%
Holding
159
New
12
Increased
33
Reduced
61
Closed
13
Top Buys
| 1 |
Louisiana-Pacific
LPX
|
$66.3M |
| 2 |
LyondellBasell Industries
LYB
|
$64.7M |
| 3 |
Ulta Beauty
ULTA
|
$39.8M |
| 4 |
Wabtec
WAB
|
$36.9M |
| 5 |
X
US Steel
X
|
$23.9M |
Top Sells
| 1 |
Booking.com
BKNG
|
$91.4M |
| 2 |
Alibaba
BABA
|
$84.4M |
| 3 |
Alphabet (Google) Class C
GOOG
|
$58.6M |
| 4 |
Vail Resorts
MTN
|
$53.5M |
| 5 |
GOGL
Golden Ocean Group
GOGL
|
$45.8M |
Sector Composition
| 1 | Consumer Discretionary | 25.71% |
| 2 | Industrials | 21.51% |
| 3 | Technology | 19.57% |
| 4 | Materials | 8.65% |
| 5 | Communication Services | 8.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
LivaNova
LIVN
$3.08B
| $2.76M | 0.06% | 41,603 | – | – |
|
77
HUTCHMED
HCM
$2.58B
| $2.72M | 0.06% | 85,055 | – | – |
|
78
IDEAYA Biosciences
IDYA
$2.15B
| $2.7M | 0.06% | 193,123 | – | – |
|
79
Analog Devices
ADI
$124B
| $2.68M | 0.06% | 18,145 +977 | +6% | +$144K |
|
80
Denali Therapeutics
DNLI
$2.23B
| $2.58M | 0.06% | 30,791 -40,002 | -57% | -$3.35M |
|
81
Zymeworks
ZYME
$1.12B
| $2.47M | 0.06% | 52,327 | – | – |
|
82
Immatics
IMTX
$619M
| $2.47M | 0.06% | 228,960 | – | – |
|
83
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $2.47M | 0.06% | 142,034 | – | – |
|
84
Intellia Therapeutics
NTLA
$1.22B
| $2.45M | 0.06% | 44,963 -20,068 | -31% | -$1.09M |
|
85
Leap Therapeutics
LPTX
$12M
| $2.4M | 0.06% | 1,065,259 +644,788 | +153% | +$1.45M |
|
86
BioAtla
BCAB
$26.7M
| $2.38M | 0.05% | +70,000 | New | +$2.38M |
|
87
Bio-Rad Laboratories Class A
BIO
$8.06B
| $2.35M | 0.05% | 4,024 +1,662 | +70% | +$969K |
|
88
Arcus Biosciences
RCUS
$1.13B
| $2.26M | 0.05% | 87,058 | – | – |
|
89
Oracle
ORCL
$635B
| $2.06M | 0.05% | 31,874 -122 | -0.4% | -$7.89K |
|
90
Revvity
RVTY
$10.5B
| $2.04M | 0.05% | 14,180 -5,873 | -29% | -$843K |
|
91
CytomX Therapeutics
CTMX
$336M
| $1.99M | 0.05% | 303,465 +103,241 | +52% | +$676K |
|
|
INBX
92
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.98M | 0.05% | 60,105 -14,895 | -20% | -$491K |
|
|
BCEL
93
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $1.93M | 0.04% | 119,751 | – | – |
|
94
Arcturus Therapeutics
ARCT
$462M
| $1.92M | 0.04% | +44,333 | New | +$1.92M |
|
95
Roku
ROKU
$14.2B
| $1.88M | 0.04% | 5,661 -1,737 | -23% | -$577K |
|
96
Adaptive Biotechnologies
ADPT
$2.01B
| $1.78M | 0.04% | 30,028 | – | – |
|
|
XLRN
97
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.78M | 0.04% | 13,872 | – | – |
|
98
Apple
AAPL
$3.45T
| $1.7M | 0.04% | 12,788 | – | – |
|
99
Intel
INTC
$107B
| $1.69M | 0.04% | 33,932 -252,463 | -88% | -$12.6M |
|
100
Wave Life Sciences
WVE
$1.53B
| $1.62M | 0.04% | 206,384 | – | – |
|